Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
I-Mab Biopharma US Limited
Study ID
NCT04869501
Status
No Longer Available

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • TJ004309 — DRUG
    Antibody to CD73
  • Atezolizumab — DRUG
    Humanized monoclonal antibody to PD-L1

Study Details

This expanded access protocol was designed to provide TJ004309 in combination with atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to continue with treatment.

Key Dates

Status verified
Apr 2023

Locations (3)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294-
HonorHealth Research InstituteScottsdaleArizona85258-
Arizona Oncology Associates, P.C.TucsonArizona85704-

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham· Birmingham, ALHonorHealth Research Institute· Scottsdale, AZArizona Oncology Associates, P.C.· Tucson, AZ

Related Studies